Evidence map›Paper›PMID 32020040›Full record

ReviewNature reviews. Urology2020

Checkpoint inhibitor immunotherapy in kidney cancer.

Wenxin Xu, Michael B Atkins, David F McDermott

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 161 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
161citing papers in PubMed, 6 pooled it
25.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

161 citing papers in PubMed, 6 syntheses or guidelines pooled it, 267 citations in OpenAlex.

  1. Recent advances in diagnostic and therapeutic approaches for pulmonary enteric adenocarcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Pooled it
  2. Pooled it
  3. New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021
    Guideline
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020
    Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Functionally heterogeneous intratumoral CD4Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  20. Review

101 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Wenxin XuBeth Israel Deaconess Medical Center, Boston, MA, USA.ORCID http://orcid.org/0000-0002-8450-2037
Michael B AtkinsMedStar Georgetown University Hospital, Washington, DC, USA.
David F McDermottBeth Israel Deaconess Medical Center, Boston, MA, USA. dmcdermo@bidmc.harvard.edu.ORCID http://orcid.org/0000-0002-2675-5095
Beth Israel Deaconess Medical Center · USGeorgetown University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kidney cancer has unique features that make this malignancy attractive for therapeutic approaches that target components of the immune system. Immune checkpoint inhibition is a well-established part of kidney cancer treatment, and rapid advances continue to be made in this field. Initial preclinical studies that elucidated the biology of the programmed cell death 1 (PD-1), programmed cell death 1 ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) immune checkpoints led to a series of clinical trials that resulted in regulatory approval of nivolumab and the combination of ipilimumab plus nivolumab for the treatment of advanced renal cell carcinoma. Subsequent data led to approvals of combination strategies of immune checkpoint inhibition plus agents that target the vascular endothelial growth factor receptor and a shift in the current standard of renal cell carcinoma care. However, controversies remain regarding the optimal therapy selection and treatment strategy for individual patients, which might be eventually overcome by current intensive efforts in biomarker research. That work includes evaluation of tumour cell PD-L1 expression, gene expression signatures, CD8

Indexed as

Antineoplastic Agents, ImmunologicalB7-H1 AntigenCarcinoma, Renal CellCell Cycle CheckpointsCTLA-4 AntigenDrug Therapy, CombinationHumansImmunotherapyKidney NeoplasmsProgrammed Cell Death 1 ReceptorAntineoplastic Agents, ImmunologicalB7-H1 AntigenCTLA-4 AntigenPDCD1 protein, humanProgrammed Cell Death 1 Receptor

Identifiers

PMID32020040
OpenAlexW3005088442

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.